Towards peptide-substituted titanocene anticancer drugs

详细信息    查看全文

• 作者：Johannes Zagermann^a ; Anthony Deally^b ; Nils Metzler-Nolte^a ; Helge Mü ; ller-Bunz^b ; Denise Wallis^b ; Matthias Tacke^b ; ^{matthias.tacke@ucd.ie"" rel=""nofollow}
• 关键词：Bioorganometallic chemistry ; Metal-based anticancer drugs ; Titanocene dichloride ; [3+2] Cycloaddition ; Targeting vector ; Enkephalin
• 刊名：Polyhedron
• 出版年：2011
• 出版时间：30 August 2011
• 年：2011
• 卷：30
• 期：14
• 页码：2387-2390
• 全文大小：317 K

文摘

An alkyne-substituted fulvene was transformed via hydridolithiation followed by transmetallation with titanium tetrachloride into bis-[p-(prop-2-ynyloxy)-benzyl-cyclopentadienyl] titanium(IV) dichloride. Single crystals of this titanocene derivative could be obtained and the structure determined by X-ray diffraction. It showed that this compound crystallises in the space group C2/c with four molecules in the monoclinic cell. The alkyne-substituted titanocene dichloride derivative was then subject to a copper-catalysed azide–alkyne cycloaddition with its azide-functionalised methylester-protected phenylalanine reaction partner in order to form a linking triazole. This reaction was performed under anhydrous conditions employing a dichloromethane/acetonitrile solvent mixture with copper(I) iodide and 2,6-lutidine as the catalyst system. Under these conditions the adduct between the protein mimic and the titanocene was formed without hydrolysing the titanium dichloride moiety.